# Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

> **NCT04288726** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 18 (estimated)

## Conditions studied

- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Classical Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CD30.CAR-EBVST cells

## Key facts

- **NCT ID:** NCT04288726
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-16
- **Primary completion:** 2026-06-01
- **Final completion:** 2037-06-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04288726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04288726, "Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04288726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*